ClinicalTrials.Veeva

Menu

Cost Effectiveness Of Linezolid In Central America

Pfizer logo

Pfizer

Status

Withdrawn

Conditions

Ventilator Acquired Pneumonia

Treatments

Drug: Linezolid

Study type

Observational

Funder types

Industry

Identifiers

NCT01040585
A5951154

Details and patient eligibility

About

The therapy with Linezolid (LIN) represents better cost-effectiveness vs. Vancomycin (VAN) for the treatment of nosocomial Pneumonia associate to ventilator (VAP).

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Evidence of a legally acceptable representative signed and dated informed consent document indicating that him or her has been informed of all pertinent aspects of the study.
  • Adult (18 years old or older) men and women with confirm diagnosis of VAP treated on ICU with LIN or VAN; on the selected institutions.

Exclusion criteria

  • Adult men or women with nosocomial pneumonia not associated to a ventilator.

Trial design

0 participants in 1 patient group

Central America and the Caribbean
Description:
Panama, Costa Rica, Honduras, El Salvador and Nicaragua
Treatment:
Drug: Linezolid

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems